FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.
Healio5d
Vistagen receives US patent for nonopioid neuropathic pain therapy
The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced ...
Impacts14d
Fast-Acting Anxiety Relief: How Ketamine Works on the Brain
Why We Need Fast-Acting Anxiety Relief Now More Than Ever Anxiety isn’t just feeling nervous before a big event—it can be relentless, overwhelming, and even debilitating. Traditional treatments like ...
Hosted on MSN2mon
Innovative protocol maps NMDA receptors in Alzheimer's-affected brains
In this study, recently published in Alzheimer's & Dementia, the authors investigated NMDA (N-methyl-D-aspartate receptors) receptors due to their importance in synaptic transmission and their ...
Monthly Prescribing Reference11y
Namenda Xr
Caution with other NMDA antagonists (eg, amantadine, ketamine, dextromethorphan). May affect or be affected by renally-excreted drugs (eg, triamterene, HCTZ, metformin, cimetidine, nicotine ...
MedPage Today23d
FDA Expands Approval of Esketamine for Depression
The drug acts as a non-selective, non-competitive antagonist of the NMDA receptor and works by targeting glutamate in the brain. While it is estimated that 21 million U.S. adults are living with ...
Nature19y
Potentiation of Low Dose Ketamine Effects by Naltrexone: Potential Implications for the Pharmacotherapy of Alcoholism
The interplay of opiate and NMDA glutamate receptors may contribute to psychosis, cognitive function, alcoholism, and substance dependence. Ketamine and ethanol block the NMDA glutamate receptor.